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Abstract Electronic health records (EHRs) provide
opportunities to enhance patient care, embed performance
measures in clinical practice, and facilitate clinical
research. Concerns have been raised about the increasing
recruitment challenges in trials, burdensome and obtrusive
data collection, and uncertain generalizability of the
results. Leveraging electronic health records to counter-
balance these trends is an area of intense interest. The
initial applications of electronic health records, as the pri-
mary data source is envisioned for observational studies,
embedded pragmatic or post-marketing registry-based
randomized studies, or comparative effectiveness studies.
Advancing this approach to randomized clinical trials,
electronic health records may potentially be used to assess
study feasibility, to facilitate patient recruitment, and
streamline data collection at baseline and follow-up.
Ensuring data security and privacy, overcoming the chal-
lenges associated with linking diverse systems and main-
taining infrastructure for repeat use of high quality data, are
some of the challenges associated with using electronic
health records in clinical research. Collaboration between
academia, industry, regulatory bodies, policy makers,
patients, and electronic health record vendors is critical for
the greater use of electronic health records in clinical re-
search. This manuscript identifies the key steps required to
advance the role of electronic health records in cardio-
vascular clinical research.
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Introduction
Electronic health records (EHRs) provide opportunities to
enhance patient care, to embed performance measures in
clinical practice, and to improve the identification and
recruitment of eligible patients and healthcare providers in
clinical research. On a macroeconomic scale, EHRs (by
enabling pragmatic clinical trials) may assist in the
assessment of whether new treatments or innovation in
healthcare delivery result in improved outcomes or
healthcare savings.
Concerns have been raised about the current state of
cardiovascular clinical research: the increasing recruit-
ment challenges; burdensome data collection; and uncer-
tain generalizability to clinical practice [1]. These factors
add to the increasing costs of clinical research [2] and are
thought to contribute to declining investment in the field
[1].
The Cardiovascular Round Table (CRT) of the Euro-
pean Society of Cardiology (ESC) convened a two-day
workshop among international experts in cardiovascular
clinical research and health informatics to explore how
EHRs could advance cardiovascular clinical research. This
paper summarizes the key insights and discussions from the
workshop, acknowledges the barriers to EHR implemen-
tation in clinical research, and identifies practical solutions
for engaging stakeholders (i.e., academia, industry, regu-
latory bodies, policy makers, patients, and EHR vendors) in
the implementation of EHRs in clinical research.
Overview of electronic health records
Broadly defined, EHRs represent longitudinal data (in
electronic format) that are collected during routine
delivery of health care [3]. EHRs generally contain
demographic, vital statistics, administrative, claims
(medical and pharmacy), clinical, and patient-centered
(e.g., originating from health-related quality-of-life
instruments, home-monitoring devices, and frailty or
caregiver assessments) data. The scope of an EHR varies
widely across the world. Systems originating primarily as
billing systems were not designed to support clinical work
flow. Moving forward, EHR should be designed to opti-
mize diagnosis and clinical care, which will enhance their
relevance for clinical research. The EHR may reflect
single components of care (e.g., primary care, emergency
department, and intensive care unit) or data from an
integrated hospital-wide or inter-hospital linked system
[4]. EHRs may also change over time, reflecting evolving
technology capabilities or external influences (e.g., chan-
ges in type of data collected related to coding or reim-
bursement practices).
EHRs emerged largely as a means to improve healthcare
quality [5–7] and to capture billing data. EHRs may
potentially be used to assess study feasibility, facilitate
patient recruitment, streamline data collection, or conduct
entirely EHR-based observational, embedded pragmatic, or
post-marketing randomized registry studies, or compara-
tive effectiveness studies. The various applications of
EHRs for observational studies, safety surveillance, clini-
cal research, and regulatory purposes are shown in Table 1
[3, 8–10].
Electronic health records for research applications
Epidemiologic and observational research
EHR data have been used to support observational studies,
either as stand-alone data or following linkage to primary
research data or other administrative data sets [3, 11–14].
For example, the initial Euro Heart Survey [15] and sub-
sequent Eurobservational Research Program (EORP) [16],
the American College of Cardiology National Cardiovas-
cular Data Registry (ACC-NCDR) [14], National Registry
of Myocardial Infarction (NRMI), and American Heart
Association Get With the Guidelines (AHA GWTG) [17]
represent clinical data (collected from health records into
an electronic case report form [eCRF] designed for the
specific registry) on the management of patients across a
spectrum of different cardiovascular diseases. However,
modern EHR systems can minimize or eliminate the need
for duplicate data collection (i.e., in a separate registry-
specific eCRF), are capable of integrating large amounts of
medical information accumulated throughout the patient’s
life, enabling longitudinal study of diseases using the
existing informatics infrastructure [18]. For example, EHR
systems increasingly house imaging data which provide
more detailed disease characterization than previously
available in most observational data sets. In some countries
(e.g., Farr Institute in Scotland [19]), the EHR can be
linked, at an individual level, to other data sets, including
general population health and lifestyle surveys, disease
registries, and data collected by other sectors (e.g., edu-
cation, housing, social care, and criminal justice). EHR
data support a wide range of epidemiological research on
the natural history of disease, drug utilization, and safety,
as well as health services research.
Safety surveillance and regulatory uses
Active post-marketing safety surveillance and signal
detection are important, emerging applications for EHRs,
because they can provide realistic rates of events (unlike
spontaneous event reports) and information on real-world
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use of drugs [20]. The EU-ADR project linked 8 databases
in four European countries (Denmark, Italy, The Nether-
lands, United Kingdom) to enable analysis of select target
adverse drug events [21]. The European Medicines Agency
(EMA) coordinates the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCePP)
which aims to conduct post-marketing risk assessment
using various EHR sources [22, 23]. In the United States,
the Food and Drug Administration (FDA) uses EHR data
from several different sources (e.g., Sentinel and Mini-
Sentinel System [24], Centers for Medicare and Medicaid
Services [CMS], Veterans Affairs, Department of Defense,
Substance Abuse and Mental Health Services Administra-
tion) to support post-marketing safety investigations [25].
Prospective clinical research
National patient registries that contain data extracted from
the EHR are an accepted modality to assess guideline
adherence and the effectiveness of performance improve-
ment initiatives [26–33]. However, the use of EHRs for
prospective clinical research is still limited, despite the fact
that data collected for routine medical care overlap con-
siderably with data collected for research. The most
straightforward and generally accepted application for
EHR is assessing trial feasibility and facilitating patient
recruitment, and EHRs are currently used for this purpose
in some centers. Using EHR technology to generate lists of
patients who might be eligible for research is recognized as
an option to meet meaningful use standards for EHR in the
United States [6]. However, incomplete data may prohibit
screening for the complete list of eligibility criteria [34],
but EHRs may facilitate pre-screening of patients by age,
gender, and diagnosis, particularly for exclusion of ineli-
gible patients, and reduce the overall screening burden in
clinical trials [35]. A second, and more complex, step
involves the reuse of information collected in EHRs for
routine clinical care as source data for research. Using
EHRs as the source for demographic information, co-
morbidities, and concomitant medications has several
advantages over separately recording these data into an
eCRF. Transcription errors may be reduced, since EHR
data are entered by providers directly involved in a
patient’s care as opposed to secondary eCRF entry by study
personnel. The eCRF may be a redundant and costly step in
a clinical trial, since local health records (electronic or
paper) are used to verify source data entered into the eCRF.
Finally, EHRs might enhance patient safety and reduce
Table 1 Electronic health records in research
Type Example Status
Observational studies Health utilization
Drug utilization
Epidemiology (incidence/prevalence)
Natural history
Risk factors
Widely used and accepted
Safety surveillance Traditional post-marketing safety surveillance Widely used and accepted
Active surveillance (e.g., Sentinela) Emerging
Clinical research Hypothesis generation Accepted
Feasibility assessments Accepted
Performance improvement, guideline adherence Accepted
Patient recruitment Emerging
Comparative effectiveness, health technology assessments Emerging
Pragmatic trials (e.g. PROBE design) Emerging
Point of care randomization Emerging
Registry randomized trials to test new interventions Emerging
Source data to populate eCRF (eliminating or minimizing need
for data extraction/data entry)
Emerging/potential
Endpoint or SAE ascertainment Emerging/potential
Regulatory Safety surveillance, pharmacovigilance Accepted
New indications or marketing authorization Potential
a Sentinel is the United States Food and Drug Administration’s national electronic system to proactively monitor medical product safety post-
marketing, through rapidly and securely accessing data from large amounts of electronic healthcare records, insurance claims, and registries,
from a diverse group of data partners [24]
PROBE prospective randomized open blinded endpoint, eCRF electronic case report form, SAE serious adverse event
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timelines if real-time EHR systems are used in clinical
trials, in contrast to delays encountered with manual data
entry into an eCRF. The EHR may facilitate implementa-
tion of remote data monitoring, which has the potential to
greatly reduce clinical trial costs. The Innovative Medicine
Initiative (IMI) Electronic Health Records for Clinical
Research (EHR4CR, http://www.ehr4cr.eu) project is one
example, where tools and processes are being developed to
facilitate reuse of EHR data for clinical research purposes.
Systems to assess protocol feasibility and identify eligible
patients for recruitment have been implemented, and
efforts to link EHRs with clinical research electronic data
collection are ongoing [36].
A shift towards pragmatic trials has been proposed as a
mechanism to improve clinical trial efficiency [37]. Most
of the data in a pragmatic trial are collected in the context
of routine clinical care, which reduce trial-specific clinic
visits and assessments, and should also reduce costs [38].
This concept is being applied in the National Institutes of
Health (NIH) Health Care Systems Research Collabora-
tory. Trials conducted within the NIH Collaboratory aim to
answer questions related to care delivery and the EHR
contains relevant data for this purpose. Studies may have
additional data collection modules if variables not routinely
captured in the EHR are needed for a specific study.
Similarly, the Patient-Centered Outcomes Research Insti-
tute (PCORI) has launched PCORnet, a research network
that uses a common data platform alongside the existing
EHR to conduct observational and interventional compar-
ative effectiveness research [9, 39, 40].
The integration of EHRs in the conventional randomized
controlled trials intended to support a new indication is
more complex. EHRs may be an alternative to eCRFs when
data collection is focused and limited to critical variables
that are consistently collected in routine clinical care.
Regulatory feedback indicates that while a new indication
for a marketed drug might be achieved through EHRs, first
marketing authorization using data entirely from EHRs
would most likely not be possible with current systems
until validation studies are performed and reviewed by
regulatory agencies. The EHR could also be used to collect
serious adverse events (SAE) that result in hospitalization,
or to collect endpoints that do not necessarily require
blinded adjudication (e.g., death), although the utility of
EHRs for this purpose is dependent on the type of endpoint,
whether it can reliably be identified in the EHR, and the
timeliness of EHR data availability. Events that are coded
for reimbursement (e.g., hospitalizations, MI) or new
diagnoses, where disease-specific therapy is initiated (e.g.,
initiation of glucose lowering drugs to define new onset
diabetes) tend to be more reliable. The reliability of end-
point collection varies by region and depends on the extent
of linkage between different databases.
Challenges to using electronic health records
in clinical trials and steps toward solutions
Challenges to using EHRs in clinical trials have been
identified, related to data quality and validation, complete
data capture, heterogeneity between systems, and devel-
oping a working knowledge across systems (Table 2).
Ongoing projects, such as those conducted within the NIH
Collaboratory and PCORnet [39, 41] in the United States or
the Farr Institute of Health Informatics Research in Scot-
land, have demonstrated the feasibility of using EHRs for
aspects of clinical research, particularly comparative
effectiveness. The success of these endeavors is connected
to careful planning by a multi-stakeholder group commit-
ted to patient privacy, data security, fair governance, robust
data infrastructure, and quality science from the outset. The
next hurdle is to adapt the accrued knowledge for appli-
cation to a broader base of clinical trials.
Data quality and validation
Data quality and validation are key factors in determining
whether EHRs might be suitable data sources in clinical
trials. Concerns about coding inaccuracies or bias intro-
duced by selection of codes driven by billing incentives
rather than clinical care may be diminished when health-
care providers enter data directly into the EHRs or when
EHRs are used throughout all areas of the health-system,
but such systems have not yet been widely implemented
[42]. Excessive or busy workloads may also contribute to
errors in clinician data entry [43]. Indeed, errors in EHRs
have been reported [43–45].
Complete data capture is also a critical aspect of using
EHRs for clinical research, particularly if EHRs are used
for endpoint ascertainment or SAE collection. Complete
data capture can be a major barrier in regions, where
patients receive care from different providers or hospitals
operating in different EHR systems that are not linked.
Consistent, validated methods for assessing data quality
and completeness have not yet been adopted [46], but
validation is a critical factor for the regulatory acceptance
of EHR data. Proposed validation approaches include using
both an eCRF and EHRs in a study in parallel and com-
paring results using the two data collection methods. This
approach will require collaborative efforts to embed EHR
substudies in large cardiovascular studies conducted by
several sponsors. Assessing selected outcomes of interest
from several EHR-based trials to compare different
methodologies with an agreed statistical framework will be
required to gauge precision of data collection via EHRs. A
hybrid approach has also been proposed, where the EHR is
used to identify study endpoints (e.g., death, hospitaliza-
tion, myocardial infarction, and cancer), followed by
4 Clin Res Cardiol (2017) 106:1–9
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adjudication and validation of EHR findings using clinical
data (e.g., electrocardiogram and laboratory data).
Validity should be defined a priori and should be
specific to the endpoints of interest as well as relevant to
the country or healthcare system. Validation studies should
aim to assess both the consistency between EHR data and
standard data collection methods, and also how identified
differences influence a study’s results. Proposed uses of
EHRs for registration trials and methods for their valida-
tion will likely be considered by regulatory agencies on a
case-by-case basis, because of the limited experience with
EHRs for this purpose at the current time. Collaboration
among industry sponsors to share cumulative experiences
with EHR validation studies might lead to faster accep-
tance by regulatory authorities.
The ESC-CRT recommends that initial efforts to inte-
grate EHRs in clinical trials focus on a few efficacy end-
points of interest, preferably objective endpoints (e.g., all-
cause or cause-specific mortality) that are less susceptible
to bias or subjective interpretation. As noted above, mor-
tality may be incompletely captured in EHRs, particularly
if patients die outside of the hospital, or at another
institution using a non-integrated EHR. Thus, methods to
supplement endpoint ascertainment in the EHR may be
necessary if data completeness is uncertain. Standardized
endpoint definitions based on the EHR should be included
in the study protocol and analysis plan. A narrow set of
data elements for auditing should be prospectively defined
to ensure the required variables which are contained in the
EHR.
Early interaction between sponsors, clinical investiga-
tors, and regulators is recommended to enable robust
designs for clinical trials aiming to use EHRs for endpoint
ascertainment. Plans to translate Good Clinical Practice
into an EHR facilitated research environment should be
described. Gaps in personnel training and education should
be identified and specific actions to address training defi-
ciencies should be communicated to regulators and in place
prior to the start of the trial.
Timely access to electronic health record data
The potential for delays in data access is an important
consideration when EHRs are used in clinical trials. EHRs
Table 2 Challenges of using electronic health records in research
Problem Example Potential Solutions
Data quality
and
validation
Selecting measurement of interest for a clinical trial
when multiple measurements are available (e.g.,
laboratory data)
Inaccurate information in EHRs
Coding errors
Specific parameters (e.g., using date or time windows) stated in
protocol or operating procedures for extracting data from EHR
into eCRF
Use codes linked to reimbursement, which have greater likelihood
of reliability
Stakeholder collaboration to develop validation methodology
Stakeholder collaboration to contribute data for EHR validation
studies
Complete data
capture
Clinical endpoints
SAEs
Problematic in multiple-payer systems
Death
Develop standards for data sharing and privacy
Explore linking EHRs to national death registries
Heterogeneity
among
systems
Multiple different vendors within a given country or
region
Inconfigurable systems
Lack of flexible architecture
Lack of common data fields, data definitions, and
difficulty with data mapping
Incomplete data capture
Missing fields of interest (i.e. relevant to some diseases
but not others)
Inability to link systems (i.e. different patient identifiers)
Commit resources to harmonization efforts
Form working group with representation from all stakeholders to
develop consensus agreement on a common set of data variables
to be included in all systems
System
knowledge
Inadequate understanding of database and its structure
Researchers may not understand limitations of database
Transparency
Develop and maintain data standards and operations manuals
Report strengths, limitations, and nuances of databases in primary
manuscripts
Informatics training for investigators
EHR electronic health record, SAE serious adverse event
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may contain data originally collected as free text that was
later coded for the EHR. Thus, coded information may not
be available for patient identification/recruitment during
the admission. Similarly, coding may occur weeks or
months after discharge. In nationally integrated systems,
data availability may also be delayed. These delays may be
critical depending on the purpose of data extracted from the
EHR (e.g., SAE reporting, source data, or endpoints in a
time-sensitive study).
Heterogeneity between systems
Patients may be treated by multiple healthcare providers
who operate independently of one another. Such patients
may have more than one EHR, and these EHRs may not be
linked. This heterogeneity adds to the complexity of using
EHRs for clinical trials, since data coordinating centres
have to develop processes for interacting or extracting data
from any number of different systems. Differences in
quality [47], non-standardized terminology, incomplete
data capture, issues related to data sharing and data pri-
vacy, lack of common data fields, and the inability of
systems to be configured to communicate with each other
may also be problematic. Achieving agreement on a min-
imum set of common data fields to enable cross commu-
nication between systems would be a major step forward
towards enabling EHRs to be used in clinical trials across
centers and regions [48, 49].
Data security and privacy
Privacy issues and information governance are among the
most complex aspects of implementing EHRs for clinical
research, in part because attitudes and regulations related to
data privacy vary markedly around the world. Data security
and appropriate use are high priorities, but access should
not be restricted to the extent that the data are of limited
usefulness. Access to EHR data by regulatory agencies will
be necessary for auditing purposes in registration trials.
Distributed analyses have the advantage of allowing data to
remain with the individual site and under its control
[39, 41].
Pre-trial planning is critical to anticipate data security
issues and to develop optimal standards and infrastructure.
For pivotal registration trials, patients should be informed
during the consent process about how their EHRs will be
used and by whom. Modified approaches to obtaining
informed consent for comparative effectiveness research
studies of commonly used clinical practices or interven-
tions may be possible [50]. A general upfront consent
stating that EHR data may be used for research is a
proactive step that may minimize later barriers to data
access, although revision of existing legislation or ethics
board rules may be needed to allow this approach. Patients
and the public should be recognized as important stake-
holders, and they can be advocates for clinical research
using EHRs and improve the quality of EHR-based
research if they are educated and engaged in the process
and the purpose and procedures for EHR use are trans-
parent. Developing optimal procedures for ensuring
patients that are informed and protected, balanced with
minimizing barriers to research is a major consideration as
EHR-based research advances.
System capabilities
EHRs for use in clinical research need a flexible architec-
ture to accommodate studies of different interventions or
disease states. EHR systems may be capable of matching
eligibility criteria to relevant data fields and flagging
potential trial subjects to investigators. Patient question-
naires and surveys can be linked to EHRs to provide
additional context to clinical data. Pre-population of eCRFs
has been proposed as a potential role for EHRs, but the
proportion of fields in an EHR that can be mapped to an
eCRF varies substantially across systems.
EHRs may be more suitable for pragmatic trials where
data collection mirrors those variables collected in routine
clinical care. Whether regulators would require collection
of additional elements to support a new drug or new
indication depends on the drug, intended indication, patient
population, and potential safety concerns.
Sustainability
The sustainability of EHRs in clinical research will largely
depend on the materialization of their promised efficien-
cies. Programs like the NIH Collaboratory [41] and
PCORnet [39, 41], and randomized registry trials [51, 52]
are demonstrating the feasibility of these more efficient
approaches to clinical research. The sustainability of using
EHRs for pivotal registration clinical trials will depend on
regulatory acceptance of the approach and whether the
efficiencies support a business case for their use.
Role of stakeholders
To make the vision of EHRs in clinical trials a reality,
stakeholders should collaborate and contribute to the
advancement of EHRs for research. Professional bodies,
such as the ESC, can play a major role in the training and
education of researchers and the public about the potential
value of EHR. Clinical trialists and industry must be
committed to advancing validation methodology [53].
Investigators should develop, conduct, and promote
6 Clin Res Cardiol (2017) 106:1–9
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institutional EHR trials that change clinical practice; such
experience may encourage EHR trial adoption by industry
and the agencies. Development of core or minimal data sets
could streamline the process, reduce redundancy and
heterogeneity, and decrease start-up time for future EHR-
based clinical trials. These and other stakeholder contri-
butions are outlined in Table 3.
Conclusion
Electronic health records are a promising resource to
improve the efficiency of clinical trials and to capitalize on
novel research approaches. EHRs are useful data sources to
support comparative effectiveness research and new trial
designs that may answer relevant clinical questions as well
as improve efficiency and reduce the cost of cardiovascular
clinical research. Initial experience with EHRs has been
encouraging, and accruing knowledge will continue to
transform the application of EHRs for clinical research.
The pace of technology has produced unprecedented ana-
lytic capabilities, but these must be pursued with appro-
priate measures in place to manage security, privacy, and
ensure adequacy of informed consent. Ongoing programs
have implemented creative solutions for these issues using
distributed analyses to allow organizations to retain data
control and by engaging patient stakeholders. Whether
EHRs can be successfully applied to the conventional drug
development in pivotal, registration trials remains to be
seen and will depend on demonstration of data quality and
validity, as well as realization of expected efficiencies.
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